ivermectin for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. antiviral and associated therapy
vs. chloroquine and derivatives
vs. hydroxychloroquine
vs. hydroxychloroquine plus macrolides
vs. lopinavir/ritonavir
vs. control
vs. placebo
vs. standard of care
vs. Vitamins
vs. vitamin C

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 4

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

NCT04429711 (Biber), 2020 NCT04429711

ivermectin (n=100) vs. placebo (n=-9)

randomized controlled trial

Studied treatment

ivermectin
12-15mg/ day for 3 days

Control treatment

placebo

Patients

COVID-19 (hospitalized or not)

Method

double blind

1 center, Israel

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open